Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The emergence of CRISPR nucleases has transformed biotechnology by providing an easy, efficient and versatile platform for editing DNA. However, traditional CRISPR-based technologies initiate editing by activating DNA double-strand break repair pathways, which can cause adverse effects in cells and restrict certain therapeutic applications of the technology. To this end, several new CRISPR-based modalities have been developed that are capable of catalyzing editing without the requirement for a double-strand break. Here we review three of these technologies – base editors, prime editors and RNA-targeting Cas13 effectors. We discuss their strengths compared to traditional gene-modifying systems, we highlight their emerging therapeutic applications, and we examine challenges facing their safe and effective clinical implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437 · cited 1×
“To date, several different base editors have been developed for use in mammalian cells (Figure 1A,B), including cytosine base editors (CBEs), which can catalyze the deamination of a target cytosine to facilitate its conversion to a thymine [28,29], adenosine base editors (ABEs), which can deaminate a target adenosine…”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 1×
“To date, several different base editors have been developed for use in mammalian cells (Figure 1A,B), including cytosine base editors (CBEs), which can catalyze the deamination of a target cytosine to facilitate its conversion to a thymine [28,29], adenosine base editors (ABEs), which can deaminate a target adenosine…”
BackgroundAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Kosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
TALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650
Evolved Cas9 variants with broad PAM compatibility and high DNA specificity
Hu, J. H., Miller, S. M., Geurts, M. H., Tang, W., Chen, L., Sun, N., Zeina, C. M., Gao, X., Rees, H. A., Lin, Z., et al. (2018) · Nature · doi:10.1038/nature26155 · Cited by 1,552
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · cited 1×
“In fact, within only 6 years of the first reports demonstrating their ability to edit DNA in mammalian cells [8,10,11], CRISPR systems were used to successfully edit immune cells which were then safely transplanted to cancer patients [12,13].”
Background
Cited by
Current understanding of osteoarthritis pathogenesis and relevant new approaches
Tong, L., Yu, H., Huang, X., Shen, J., Xiao, G., Chen, L., Wang, H., Xing, L., & Chen, D. (2022) · Bone Research · doi:10.1038/s41413-022-00226-9 · Cited by 437
Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing
Duan, L., Ouyang, K., Wang, J., Xu, L., Xu, X., Wen, C., Xie, Y., Liang, Y., & Xia, J. (2021) · ChemBioChem · doi:10.1002/cbic.202100359 · Cited by 82
Siles, L., Ruiz-Nogales, S., Navinés-Ferrer, A., Méndez-Vendrell, P., & Pomares, E. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.02.032 · Cited by 29
Metadata
- Authors
- Zeballos C., M. A., & Gaj, T.
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 39
- Issue
- 7
- Pages
- 692-705
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W3109253806
- Cited by
- 94
- References
- 46
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. https://app.cochat.ai/papers/10.1016/j.tibtech.2020.10.010
- The paper
- Zeballos C., M. A., & Gaj, T. (2021). Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2020.10.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.